Compare SPAI & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPAI | CPIX |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 73.6M |
| IPO Year | N/A | 2007 |
| Metric | SPAI | CPIX |
|---|---|---|
| Price | $4.66 | $4.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 160.4K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,010,949.00 |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $2.47 | $1.85 |
| 52 Week High | $9.16 | $6.27 |
| Indicator | SPAI | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 68.39 |
| Support Level | $3.51 | $2.89 |
| Resistance Level | $4.71 | $4.81 |
| Average True Range (ATR) | 0.34 | 0.44 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 89.44 | 52.13 |
Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.